Brief Report - (2025) Volume 11, Issue 1
Received: 28-Jan-2025, Manuscript No. cdp-25-165810;
Editor assigned: 30-Jan-2025, Pre QC No. P-165810;
Reviewed: 13-Feb-2025, QC No. Q-165810;
Revised: 20-Feb-2025, Manuscript No. R-165810;
Published:
27-Feb-2025
, DOI: 10.37421/2572-0791.2025.11.154
Citation: Sotiras, Deanna. "Efficacy and Safety of tDCS for Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Trials." Clin Depress 11 (2025): 154.
Copyright: © 2025 Sotiras D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The Dorsolateral Prefrontal Cortex (DLPFC) is the most commonly targeted brain region in tDCS for depression, as it is involved in emotion regulation, executive functioning, and cognitive control. Neuroimaging studies have consistently shown reduced activity in the left DLPFC in individuals with depression, and evidence suggests that modulating this region with tDCS can lead to improvements in mood and cognitive function. Despite promising results from smaller studies, the overall efficacy and safety of tDCS for MDD have not been definitively established. In this context, systematic reviews and meta-analyses of Randomized Controlled Trials (RCTs) are essential for synthesizing the available evidence and providing clearer conclusions about the potential role of tDCS in treating MDD. This article aims to review and analyze the efficacy and safety of tDCS for MDD through a systematic review and meta-analysis of existing randomized trials [2].
A systematic review and meta-analysis of randomized trials provides a rigorous and comprehensive approach to assessing the effectiveness of tDCS for treating MDD. By pooling data from multiple studies, this method increases statistical power and provides a more reliable estimate of treatment effects. In the case of tDCS, various factors need to be considered, including the specific protocols used (e.g., electrode placement, current intensity, and stimulation duration), the number of treatment sessions, the characteristics of the patient population, and the outcome measures employed to assess treatment efficacy [3]. Additionally, safety data, including any adverse events associated with tDCS, must be evaluated to ensure that the treatment is both effective and well-tolerated by patients. The main objective of this meta-analysis is to examine whether tDCS is superior to placebo or sham treatments in reducing depressive symptoms, as measured by standardized depression rating scales. Furthermore, this analysis seeks to investigate whether tDCS is safe and well-tolerated in clinical populations with MDD [4].
A significant body of literature has examined the use of tDCS in individuals with MDD, with the majority of studies employing a standardized electrode montage targeting the left DLPFC. These studies have generally shown promising results, with patients receiving anodal stimulation over the left DLPFC experiencing greater improvements in depressive symptoms compared to those receiving sham or placebo treatments. Additionally, there is evidence to suggest that tDCS can have long-lasting effects, with some studies showing sustained improvements in mood and cognition even after the stimulation sessions have ended. However, the results of individual trials have been inconsistent, and the methodological quality of studies has varied considerably, which complicates the interpretation of findings. In particular, differences in treatment protocols, sample sizes, and study durations have made it difficult to draw definitive conclusions about the optimal conditions for tDCS treatment in MDD [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Clinical Depression received 89 citations as per Google Scholar report